27628-06-4

Upstream product

• 1197-09-7 1-(3,4-dihydroxyphenyl)ethan-1-one 
• 100-39-0 benzyl bromide 
• 99-93-4 4-Hydroxyacetophenone 
• 1836-06-2 3-bromo-4-hydroxyacetophenone 
• 120-80-9 benzene-1,2-diol 
• 100-44-7 benzyl chloride 

Downstream Products

• 129415-57-2 (E)-3-Benzo[1,3]dioxol-5-yl-1-(3,4-bis-benzyloxy-phenyl)-propenone 
• 129415-60-7 (E)-3-(2,4-Bis-benzyloxy-phenyl)-1-(3,4-bis-benzyloxy-phenyl)-propenone 
• 129415-64-1 (E)-1-(3,4-Bis-benzyloxy-phenyl)-3-(2,5-dimethoxy-phenyl)-propenone 
• 129415-54-9 (E)-1-(3,4-Bis-benzyloxy-phenyl)-3-(2-methoxy-phenyl)-propenone 
• 129415-56-1 (E)-3-(3-Benzyloxy-4-methoxy-phenyl)-1-(3,4-bis-benzyloxy-phenyl)-propenone 
• 129415-62-9 (E)-1-(3,4-Bis-benzyloxy-phenyl)-3-(2,3-dimethoxy-phenyl)-propenone 
• 177963-13-2 (R)-1-(3,4-Bis-benzyloxy-phenyl)-2-chloro-ethanol 
• 119393-71-4 1-(3,4-bis-benzyloxy-phenyl)-2-[2-(2-methoxy-phenyl)-1-methyl-ethylamino]-ethanone 
• 103266-52-0 1-(3,4-bis-benzyloxy-phenyl)-2-[2-(3,4-dimethoxy-phenyl)-1-methyl-ethylamino]-ethanone 
• 1292298-96-4 2-(3,4-bis(benzyloxy)phenyl)-2-oxoethyl-4-(tert-butoxycarbonylamino)butanoate 
• 1292298-97-5 2-(3,4-dihydroxyphenyl)-2-oxoethyl-4-(tert-butoxycarbonylamino)butanoate 
• 1292298-67-9 4-(2-(3,4-dihydroxyphenyl)-2-oxoethoxy)-4-oxobutan-1-aminium-2,2,2-trifluoroacetate 
• 1386820-15-0 N-benzyl-2-(3,4-bis(benzyloxy)phenyl)-2-oxoacetamide 
• 93796-45-3 methyl 3,4-dibenzyloxyphenylglyoxylate 

Relevant academic research and scientific papers

Compound for treating diabetes and/or related disorders

The invention discloses a compound for treating diabetes and/or related disorders, specifically a method for preventing, inhibiting and/or reversing amylin amyloid fibril formation, preventing isletsof Langerhans beta-cell death, preventing and/or reversing conversion of soluble human amylin to insoluble human amylin, and preventing and inhibiting and/or reversing cytotoxic amylin fibril formation. The invention also relates to a compound for preparing drugs for preventing and/or treating amylin amyloid-associated diseases.

COMPOUNDS FOR TREATING DIABETES AND/OR RELATED CONDITIONS

Compounds useful for treating or preventing diabetes and related conditions, and for preventing, inhibiting or reversing amylin-amyloid fibril formation, preventing islets of Langerhans (Beta)-cell death, preventing or reversing the transition from soluble human amylin to insoluble human amylin, preventing and inhibiting or reversing cytotoxic amylin fibril formation. The invention relates to compounds of Formula (I) and compounds of Formula (II): (Formulae (I) and (II)).

FLUORINE-CONTAINING COMPOUND, PATTERN FORMING SUBSTRATE, PHOTODEGRADABLE COUPLING AGENT, PATTERN FORMING METHOD, COMPOUND, AND ORGANIC THIN FILM TRANSISTOR

PROBLEM TO BE SOLVED: To provide a compound that has a big difference in contact angle before and after light irradiation and is useful as a coupling agent, and an organic thin film transistor prepared by using the compound. SOLUTION: A fluorine-containin

Design, synthesis and SAR study of hydroxychalcone inhibitors of human β-secretase (BACE1)

According to the structural characteristics of isoliquiritigenin from Glycyrrhiza uralensis, a series of hydroxychalcones has been designed, synthesized and evaluated for their in vitro inhibitory activities of β-secretase (BACE1). Structure-activity relationship study suggested that inhibitory activity against BACE1 was governed to a greater extent by the hydroxyl substituent on A-and B-ring of the chalcone, and the most active compound was substituted with four hydroxyl group (17, IC50=0.27 μM).

Studies towards the synthesis of 13C-labelled anthocyanins

The anthocyanins are a class of polyphenols found in nature, which are widely distributed throughout the plant kingdom and are thought to possess antioxidant properties. Methodology previously developed in our group for the regioselective placement of 13C-atoms into aromatic rings is being applied to the synthesis of 13C-labelled anthocyanins-namely cyanidin-3-glucoside and delphinidin-3-glucoside. Copyright

Switchable columnar metallomesogens. New helical self-assembling systems

Chiral oxovanadium(IV), copper(II), and palladium(II) β-diketonates show a room-temperature columnar mesophase which undergoes ferroelectric switching. All the compounds were obtained as liquid crystals at room temperature, and crystallization or melting processes were not detected by differential scanning calorimetry carried out to -20 °C. The mesophase was investigated by optical microscopy, DSC and X-ray diffraction, and identified as a rectangular columnar (P21). The flower like texture observed for all the compounds led us to deduce a high tilt angle (ca. 40°) of the molecules with respect to the column axis. Circular dichroism has confirmed the existence of a helical arrangement within the column. This result is in accordance with the so-called columnar mode found at low frequencies (ca. 10-3 Hz) in dielectric spectroscopy studies electrooptical response of these materials has been examined by means of a photomultiplier. The results obtained can be explained by considering a strong influence of the high tilt angle found in the mesophase.